Investigation of antitumor effects of a sodium–glucose cotransporter 2 inhibitor for treatment of prostate cancer
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/crwx8576 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Lynn Cruz Lopategui und 3 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Prostate cancer (PCa) is the second most common malignancy among men worldwide. A hallmark of PCa is metabolic reprogramming, characterized by increased glucose uptake to support rapid tumor growth. Sodium–glucose cotransporter-2 (SGLT2) inhibitors are a relatively new class of antidiabetic agents that have demonstrated antitumor effects by disrupting glucose uptake and cellular energetics in various tumor models. By lowering glucose and insulin levels, improving insulin sensitivity, and reducing chronic inflammation, these agents create a metabolically unfavorable environment for tumor progression.
Zitieren
APA
Lopategui, L. C., Sheth, S., Deb, S., & Basak, D. (2026). Investigation of antitumor effects of a sodium–glucose cotransporter 2 inhibitor for treatment of prostate cancer. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/crwx8576
Vancouver
Lopategui LC, Sheth S, Deb S, Basak D. Investigation of antitumor effects of a sodium–glucose cotransporter 2 inhibitor for treatment of prostate cancer. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/crwx8576
BibTeX
@article{Lopategui2026,
author = {Lopategui, Lynn Cruz and Sheth, Sandeep and Deb, Subrata and Basak, Debasish},
title = {Investigation of antitumor effects of a sodium–glucose cotransporter 2 inhibitor for treatment of prostate cancer},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/crwx8576}
}
EUVIMED